Global Iron-52 Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Iron-52 market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
In 2025, global Iron-52 production is approximately 173 grams, with the global average market price equating to about $64,000 per gram. That year, total global production capacity for Iron-52 reaches approximately 450 grams, and the industry's average gross profit margin is around 26%. Iron-52 is an artificial radioisotope of iron with an atomic number of 26 and a mass number of 52. It has a half-life of approximately 8.3 hours and decays primarily via electron capture and positron emission, yielding manganese-52m (which has a half-life of about 21 minutes). Due to its positron-emitting properties, Iron-52 is suitable for use in Positron Emission Tomography (PET); furthermore, as its chemical behavior closely mirrors that of stable iron, it serves as a radiotracer for studying human iron metabolism, transferrin transport, bone marrow hematopoiesis, erythropoiesis, and iron distribution within the liver, spleen, and brain. Iron-52 is typically utilized in scientific research—often in the form of iron(III) chloride, iron citrate, or labeled iron compounds—rather than as a standard commercial PET radionuclide.
The upstream segment of the industry chain primarily encompasses medium-to-high-energy cyclotrons, proton or helium ion beam systems, nuclear reaction targets, target stations, radiation shielding facilities, and radiochemical separation equipment. Iron-52 is produced through specific nuclear reactions involving the bombardment of targets—such as manganese, chromium, or nickel—with protons or other charged particles; the choice of production route requires balancing factors such as yield, impurity radionuclides, target material costs, and available accelerator energy. Following production, the target material must be rapidly transferred to a hot cell, where Iron-52 is separated from manganese, chromium, cobalt, and other metallic impurities using techniques such as ion exchange, solvent extraction, or chromatography. Given Iron-52's short half-life, upstream production is characterized by regional localization, typically relying on cyclotrons situated at universities, national laboratories, or large hospitals; key barriers to entry include optimizing beam energy, target preparation, controlling radioactive impurities, and mastering remote automated operational capabilities. The midstream segment consists mainly of radioisotope laboratories, nuclear medicine research institutions, and hospital radiopharmacies, which are responsible for the rapid separation and purification of Iron-52 from irradiated targets and its formulation into chemical forms suitable for biological research. Typical products include Iron-52 citrate, Iron-52 transferrin, and Iron-52-labeled intravenous iron preparations. The midstream sector requires control over nuclide purity, radiochemical purity, specific activity, pH value, metal impurities, sterility, and endotoxin levels, as well as management of the impact of the daughter nuclide manganese-52m on PET quantification. Given iron's strong biological binding properties, the formulation must ensure that Iron-52 binds effectively to transferrin or the target iron agent without altering its pharmacokinetics due to the preparation process. Clinical studies have utilized Iron-52-labeled iron sucrose and iron-polysaccharide complexes to observe their distribution and utilization in the liver, spleen, bone marrow, and erythrocytes. The downstream sector of the industry chain primarily comprises nuclear medicine centers, hematology research institutions, neuroscience laboratories, pharmaceutical R&D companies, and medical research units. Iron-52 can be used to study iron-deficiency anemia, abnormal iron loading, bone marrow hematopoiesis, the distribution of intravenous iron agents, and erythrocyte iron utilization rates; it also enables the observation of iron uptake in the liver, spleen, bone marrow, and brain tissue. Clinical research has employed Iron-52 citrate PET to assess cerebral iron uptake in patients with Wilson's disease and utilized dual-tracer techniques with Iron-52 and Iron-59 to monitor the early distribution and long-term erythrocyte utilization of injected iron agents. However, the application of Iron-52 remains largely confined to scientific research and small-scale clinical studies; factors such as limited production facilities, a short half-life, interference from daughter nuclides, a lack of formulation standardization, and competition from established PET nuclides have hindered the development of a mature commercial supply market.
The need for research into iron metabolism-related disorders is the primary driver behind the continued development of Iron-52. Iron plays a crucial role in hemoglobin synthesis, oxygen transport, cellular energy metabolism, and various enzymatic reactions; abnormalities in its absorption, transport, storage, and utilization are linked to conditions such as iron-deficiency anemia, iron overload, hematopoietic dysfunction, and certain neurological diseases. Iron-52 exhibits biochemical behavior virtually identical to that of stable iron while also serving as a PET tracer, enabling the direct observation of the dynamic distribution of iron from serum transferrin to the liver, spleen, bone marrow, and other tissues. Previous human studies have utilized Iron-52 citrate to assess cerebral iron uptake in patients with Wilson's disease and employed Iron-52-labeled intravenous iron agents to track their utilization in the liver, spleen, bone marrow, and erythrocytes, demonstrating its irreplaceable value in investigating iron metabolism mechanisms and evaluating therapeutic agents.
The development of intravenous iron agents and hematological drugs offers clear potential applications for Iron-52. As intravenous iron agents are increasingly used to treat iron-deficiency anemia, chronic kidney disease, and other iron-deficiency-related conditions, researchers need to evaluate the rates and efficiency with which different iron complexes enter the reticuloendothelial system, bone marrow, and circulating erythrocytes. Iron-52 can directly label formulations such as iron sucrose and iron-polysaccharide complexes; PET imaging allows for the assessment of early organ distribution, while long-term studies on erythrocyte utilization facilitate the evaluation of pharmacokinetics, safety, and differences between formulations. In the future, Iron-52 is likely to serve primarily as a high-value tool for drug development rather than as a radionuclide for large-scale routine diagnostics; demand will stem largely from research into innovative iron agents, hematopoietic drugs, nutritional metabolism, and precision hematology.
Trends in production technology will focus on increasing yields, minimizing impurities, and achieving automated, rapid separation. Iron-52 is a non-conventional positron-emitting radionuclide produced via cyclotrons using enriched targets and charged-particle nuclear reactions; however, its production is constrained by factors such as accelerator energy, the cost of enriched targets, nuclear reaction cross-sections, and the control of long-lived impurities like Iron-55. The IAEA has included Iron-52 in its technical documentation regarding cyclotron-produced radionuclides and alternative production technologies; ongoing research is exploring various target materials and nuclear reaction pathways to enhance production yields and radionuclide purity. Future technological developments will focus on the recovery of enriched target materials, sealed target stations, remote hot-cell operations, automated chromatographic separation, and rapid quality control—measures designed to minimize the time between the end of irradiation and product administration, while also reducing radiation exposure for personnel.
Report Scope
This report is a detailed and comprehensive analysis for global Iron-52 market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Iron-52 market size and forecasts, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Iron-52 market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Iron-52 market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Iron-52 market shares of main players, shipments in revenue ($ Million), sales quantity (Gram), and ASP (US$/g), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Iron-52
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Iron-52 market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include NIDC(DOE IP), Eckert & Ziegler, IAEA, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Iron-52 market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market Segmentation
Market segment by Type
Purity: >99%
Purity: >98%
Market segment by Product Form
Unlabeled Iron-52 Nuclide
Iron-52 Compound
Iron-52/Manganese-52m Generator
Market segment by Production Route
Alpha-particle Bombardment of a Chromium-50 Target
Proton Bombardment of a Manganese Target
Proton Reaction with a Nickel Target
Market segment by Radionuclide Quality Grade
Research-grade Radionuclide
Preclinical Drug-grade Radionuclide
Market segment by Application
Nuclear Medicine
Environmental Research
Others
Major players covered
NIDC(DOE IP)
Eckert & Ziegler
IAEA
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Iron-52 product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Iron-52, with price, sales quantity, revenue, and global market share of Iron-52 from 2021 to 2026.
Chapter 3, the Iron-52 competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Iron-52 breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Iron-52 market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Iron-52.
Chapter 14 and 15, to describe Iron-52 sales channel, distributors, customers, research findings and conclusion.